Last reviewed · How we verify
A Prospective, Open Label, Single Arm Cohort Study to Assess the Frequency of Adverse Reactions of Locally Manufactured 123I-metaiodobenzylguanidine in Routine Clinical Use
Assessing 123 Iodine MIBG produced locally for safety while being used in clinical practice to help in patient management decisions.
Details
| Lead sponsor | Nova Scotia Health Authority |
|---|---|
| Status | WITHDRAWN |
| Start date | 2006-07 |
| Completion | 2018-12 |
Conditions
- Adrenergic Pathology
Interventions
- Administration of 123Iodine MIBG
Primary outcomes
- Safety profile of the 123Iodine MIBG — BP and Heart rate for 24 hours after injection.
Countries
Canada